MYSZ:NASDAQMy Size, Inc. Analysis

My Size, Inc. trades at $0.671, comfortably above its 20‑day (0.625) and 50‑day (0.598) simple moving averages but still well below the 200‑day SMA (0.976), suggesting short‑term momentum within a longer‑term downtrend. The 14‑day RSI sits at 58, indicating a neutral‑to‑slightly bullish stance, while the MACD line (0.013) is above its signal (0.007) and the histogram is positive, reinforcing the near‑term bullish bias. The stock currently respects a support zone near $0.547 and faces resistance around $0.70, with volume trending lower and a 30‑day volatility of roughly 75%, flagging liquidity constraints. Despite a respectable revenue growth rate of 27% YoY, operating margins are deeply negative (‑82%) and the company posts a sizable operating loss, negative cash flow, and a trailing EPS of –$1.87, underscoring severe profitability challenges. The balance sheet shows modest debt (≈$1.0 M) offset by cash of $2.3 M, yielding a low price‑to‑book (0.60) and price‑to‑sales (0.35) that appear attractive relative to the industry average PE of 36.7, yet the negative forward PE (‑0.25) and historical max drawdown of ‑66% temper optimism. Recent material news highlights EyeFitU’s expected $440 k ARR contribution to the Naiz Fit platform, which could enhance the four‑part solution suite and provide incremental top‑line lift. However, the upside potential remains speculative given the company’s cash‑burn and the nascent nature of its AI‑driven measurement offerings. Overall, the technical picture is mildly bullish, but the fundamental backdrop is weak, and the market’s extreme greed sentiment (90.21) may be inflating price expectations beyond the underlying financial reality.